Anne Pagnier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anne Pagnier has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
D. Plantaz
Pôle couple-enfant, service de soins protégés, CHU de Grenoble, boulevard de la Chantourne, 38043 Grenoble cedex, France
2 shared publicationsA. Venaille
Clinique universitaire de pédiatrie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 09, France
1 shared publication- Abelardo Queiroz Campos Araujo
Universidade Federal do Rio de Janeiro, Instituto de Neurologia Deolindo Couto, Rio de Janeiro RJ, Brazil
1 shared publication - Agnès Duquesne
Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA 6 , France
1 shared publication Ahmed Idbaih
Sorbonne Université, APHP, Institut du Cerveau–Paris Brain Institute–ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié–Salpêtrière–Charles Foix, DMU Neurosciences, Service de Neuro‐Oncologie Paris France
1 shared publicationAleksandra Maleska
Departments of Head, Spine and Neuromedicine, Clinical Research and Biomedicine, MS Center, Neurology and Research Center for Clinical Neuroimmunology and Neuroscience Basel University Hospital and University Basel Basel Switzerland
1 shared publication
Latest Publications
- 5 April 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2113-2123
Neurofilament as a biomarker of neurodegeneration in childhood Langerhans cell histiocytosis: A feasibility study on 273 patients
Summary: Neurodegeneration (ND) is a severe complication of Langerhans cell histiocytosis (LCH), often leading to progressive neurological decline. We evaluated the usefulness of using plasma and cerebrospinal fluid neurofilament light chain (p‐ and CSF‐NFL) levels as biomarkers to identify and monitor ND‐LCH. NFL levels were measured using the single‐molecule array for a subset of patients from the French National LCH Registry. NFL levels in 692 plasma and 115 CSF samples from 273 registry‐enrolled children were analysed. Based on 84 paired plasma and CSF samples from 67 patients, p‐ and CSF‐NFL levels were strongly correlated ( p < 0.0001). The areas under the receiver operating characteristics curves for ND‐LCH were 72% (95% confidence interval [CI], 64%–78%) for p‐NFL and 94% (95% CI, 88%–98%) for CSF‐NFL. The highest p‐NFL (13.7 vs. 7.2 pg/mL; z ‐score 2.3 vs. 0.6) and CSF‐NFL (436.9 vs. 65.2 pg/mL) levels were significantly higher for ND‐LCH than in no‐ND‐LCH patients, respectively ( p < 0.0001). Plasma NFL levels were not elevated at LCH diagnosis. At LCH diagnosis, p‐NFL was not predictive of ND, but it may serve as a minimally invasive screening tool for ND in LCH, although optimal timing remains to be determined.
- 5 April 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2113-2123
Neurofilament as a biomarker of neurodegeneration in childhood Langerhans cell histiocytosis: A feasibility study on 273 patients
Summary: Neurodegeneration (ND) is a severe complication of Langerhans cell histiocytosis (LCH), often leading to progressive neurological decline. We evaluated the usefulness of using plasma and cerebrospinal fluid neurofilament light chain (p‐ and CSF‐NFL) levels as biomarkers to identify and monitor ND‐LCH. NFL levels were measured using the single‐molecule array for a subset of patients from the French National LCH Registry. NFL levels in 692 plasma and 115 CSF samples from 273 registry‐enrolled children were analysed. Based on 84 paired plasma and CSF samples from 67 patients, p‐ and CSF‐NFL levels were strongly correlated ( p < 0.0001). The areas under the receiver operating characteristics curves for ND‐LCH were 72% (95% confidence interval [CI], 64%–78%) for p‐NFL and 94% (95% CI, 88%–98%) for CSF‐NFL. The highest p‐NFL (13.7 vs. 7.2 pg/mL; z ‐score 2.3 vs. 0.6) and CSF‐NFL (436.9 vs. 65.2 pg/mL) levels were significantly higher for ND‐LCH than in no‐ND‐LCH patients, respectively ( p < 0.0001). Plasma NFL levels were not elevated at LCH diagnosis. At LCH diagnosis, p‐NFL was not predictive of ND, but it may serve as a minimally invasive screening tool for ND in LCH, although optimal timing remains to be determined.
- Open Access
- 6 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdaf071
Feasibility and efficacy of MEMMAT-like regimen in heavily pretreated adult patients with recurrent malignant embryonal brain tumors: A series of 6 cases
Background: The prognosis of adult patients with recurrent malignant embryonal brain tumors remains poor due to the lack of effective and validated treatment. A metronomic and antiangiogenic chemotherapy regimen called MEMMAT was developed in children, with promising results. Additional data on feasibility, tolerance, and efficacy in adults are necessary. Methods: This retrospective observational case series included adult patients with relapsing medulloblastoma (MB) or pineoblastoma (PB) treated with MEMMAT-adapted protocol. Treatment consisted of daily oral thalidomide, fenofibrate, and celecoxib, and alternating 21-day cycles of metronomic etoposide and cyclophosphamide associated with bevacizumab and personalized intraventricular chemotherapy. Results: Four SHH-activated MB and 2 PB were included. Median duration of treatment was 12 months (range 3–21). Significant partial response occurred in 2/4 MB patients and 2/2 PB. The best responses were observed on leptomeningeal lesions. Main grade 3–4 toxicity was neutropenia in all patients (no febrile neutropenia) and lymphopenia in all but one (2 opportunistic infections). Dose adjustments in chemotherapy and thalidomide for hematotoxicity were necessary in all patients within the first 3 months. Cumulative neurotoxicity from thalidomide affected the 4 patients with prolonged treatment (1 grade 3, 3 grade 2). Rechallenge was tried in PB patients and successful (duration: 9 months). Conclusions: MEMMAT is feasible in adult patients and can lead to a significant and sustained response in recurrent malignant embryonal brain tumors. Hematotoxicity is progressive and manageable. The withdrawal of thalidomide and starting dose adjustments on chemotherapy might be discussed.
- 6 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdaf071
Open AccessFeasibility and efficacy of MEMMAT-like regimen in heavily pretreated adult patients with recurrent malignant embryonal brain tumors: A series of 6 cases
Background: The prognosis of adult patients with recurrent malignant embryonal brain tumors remains poor due to the lack of effective and validated treatment. A metronomic and antiangiogenic chemotherapy regimen called MEMMAT was developed in children, with promising results. Additional data on feasibility, tolerance, and efficacy in adults are necessary. Methods: This retrospective observational case series included adult patients with relapsing medulloblastoma (MB) or pineoblastoma (PB) treated with MEMMAT-adapted protocol. Treatment consisted of daily oral thalidomide, fenofibrate, and celecoxib, and alternating 21-day cycles of metronomic etoposide and cyclophosphamide associated with bevacizumab and personalized intraventricular chemotherapy. Results: Four SHH-activated MB and 2 PB were included. Median duration of treatment was 12 months (range 3–21). Significant partial response occurred in 2/4 MB patients and 2/2 PB. The best responses were observed on leptomeningeal lesions. Main grade 3–4 toxicity was neutropenia in all patients (no febrile neutropenia) and lymphopenia in all but one (2 opportunistic infections). Dose adjustments in chemotherapy and thalidomide for hematotoxicity were necessary in all patients within the first 3 months. Cumulative neurotoxicity from thalidomide affected the 4 patients with prolonged treatment (1 grade 3, 3 grade 2). Rechallenge was tried in PB patients and successful (duration: 9 months). Conclusions: MEMMAT is feasible in adult patients and can lead to a significant and sustained response in recurrent malignant embryonal brain tumors. Hematotoxicity is progressive and manageable. The withdrawal of thalidomide and starting dose adjustments on chemotherapy might be discussed.
- Top Cited PapersOpen Access
- 26 March 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (5)
Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation
NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor functional characterization of most NLRP3 variants hinders diagnosis despite efficient anti-IL-1 treatments. Additionally, while NLRP3 is controlled by priming and activation signals, gain-of-functions have only been investigated in response to priming. Here, we characterize 34 NLRP3 variants in vitro, evaluating their activity upon induction, priming, and/or activation signals, and their sensitivity to four inhibitors. We highlight the functional diversity of the gain-of-function mutants and describe four groups based on the signals governing their activation, correlating partly with the symptom severity. We identify a new group of NLRP3 mutants responding to the activation signal without priming, associated with frequent misdiagnoses. Our results identify key NLRP3 residues controlling inflammasome activity and sensitivity to inhibitors, and antagonistic mechanisms with broader efficacy for therapeutic strategies. They provide new insights into NLRP3 activation, an explanatory mechanism for NLRP3-AID heterogeneity, and original tools for NLRP3-AID diagnosis and drug development.
- 26 March 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (5)
Top Cited PapersOpen AccessFunctional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation
NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor functional characterization of most NLRP3 variants hinders diagnosis despite efficient anti-IL-1 treatments. Additionally, while NLRP3 is controlled by priming and activation signals, gain-of-functions have only been investigated in response to priming. Here, we characterize 34 NLRP3 variants in vitro, evaluating their activity upon induction, priming, and/or activation signals, and their sensitivity to four inhibitors. We highlight the functional diversity of the gain-of-function mutants and describe four groups based on the signals governing their activation, correlating partly with the symptom severity. We identify a new group of NLRP3 mutants responding to the activation signal without priming, associated with frequent misdiagnoses. Our results identify key NLRP3 residues controlling inflammasome activity and sensitivity to inhibitors, and antagonistic mechanisms with broader efficacy for therapeutic strategies. They provide new insights into NLRP3 activation, an explanatory mechanism for NLRP3-AID heterogeneity, and original tools for NLRP3-AID diagnosis and drug development.
- 1 January 2011
- Published by Elsevier in Archives de Pédiatrie
- Vol. 18 (1) , 33-36
Le syndrome de Vogt-Koyanagi-Harada : une urgence ophtalmologique grave et rare chez l’enfant
- 1 January 2011
- Published by Elsevier in Archives de Pédiatrie
- Vol. 18 (1) , 33-36
Le syndrome de Vogt-Koyanagi-Harada : une urgence ophtalmologique grave et rare chez l’enfant
- 1 November 2003
- Published by Elsevier in Archives de Pédiatrie
- Vol. 10 (11) , 983-985
Syndrome de Bernard-Soulier révélé par une thrombopénie sévère en période néonatale
- 1 November 2003
- Published by Elsevier in Archives de Pédiatrie
- Vol. 10 (11) , 983-985
Syndrome de Bernard-Soulier révélé par une thrombopénie sévère en période néonatale